文献速递药物不良反应与药物警戒

荷兰Lareb中心优化COVID-19疫苗安全监测的一年经验

Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
PubMed 文献 · Drug Saf · 2022-11-09

荷兰药物警戒中心Lareb为应对大规模COVID-19疫苗接种,开发了定制化报告系统与自动化流程。2021年共收到184,411份个体病例安全报告,报告率为0.67%,其中2.4%为严重事件,0.3%为致死性。

要点

  • 定制化网络报告表与自动化处理使33.1%的报告完全自动处理。
  • 每日分诊将4.2%报告标记为高优先级,62.7%为低优先级。
  • 99.9%的个体病例安全报告在合规时限内提交至Eudravigilance。

核心结论

  • 通过自动化处理已知不良事件、每日分诊和信号检测会议,Lareb在大规模疫苗接种期间完成了99.9%报告的合规时限处理。

研究设计与样本

  • 描述性研究,基于荷兰Lareb中心2021年COVID-19疫苗被动监测数据,共分析184,411份个体病例安全报告。

主要发现

  • 2021年Lareb收到184,411份个体病例安全报告,报告率为0.67%。
  • 共报告887,954例次不良事件,多数为已知非严重事件;2.4%为严重,0.3%为致死性。
  • 33.1%的个体病例安全报告被完全自动处理,4.2%经每日分诊标记为高优先级,62.7%为低优先级。

临床怎么用

  • 大规模疫苗接种期间可采用定制化报告表与自动化流程处理已知不良事件,释放人力聚焦信号评估。
  • 每日分诊与信号检测会议有助于在报告量激增时维持药物警戒质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Due to the COVID-19 vaccination campaign, national pharmacovigilance (PV) centres had to deal with high volumes of Individual Case Safety Reports (ICSRs) that needed to be processed and assessed in a short time span. This necessitated the development of a dedicated system to enable near real-time vaccine safety monitoring at the Dutch PV Centre Lareb. OBJECTIVES: To describe infrastructure, processes and Adverse Events Following Immunisation (AEFIs) reported for vaccine safety monitoring of COVID-19 vaccines during a large-scale vaccination campaign in the Netherlands. METHODS: A COVID-19 tailored vaccine web-based reporting form collected information on the vaccine administered, AEFIs and other (medical) information. A fully automated process for ICSRs enabled the handling of the majority of common and known reported AEFIs. All other ICSRs were triaged daily and processed separately. There were daily signal detection meetings and weekly reports for batch analysis. RESULTS: In 2021, Lareb received 184,411 ICSRs, a reporting rate of 0.67% for vaccines given in the Netherlands. 887,954 AEFIs were reported, mostly well-known, nonserious AEFIs; 2.4% were serious and 0.3% were fatal. 33.1% of all ICSRs were processed fully automatically. Based on the daily triage, 4.2% were flagged as 'high priority'; 62.7% as 'low-priority'. Twenty-seven signals and news stories about the COVID-19 vaccines were disseminated. CONCLUSIONS: Due to automatic processing of well-known AEFIs, daily triage and signal detection meetings, 99.9% of the ICSRs were processed within the compliance timeframe to Eudravigilance, and signal detection was performed during a large-scale vaccination campaign. These experiences may serve as a blueprint for future mass vaccination programs.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Oosterhuis I, Scholl J, van Puijenbroek E, et al. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug Saf. 2022. PMID: 36350465. doi:10.1007/s40264-022-01253-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。